Nymox Pharmaceutical (Nymox Pharmaceutical) 3-Year EBITDA Growth Rate : 27.30% (As of Sep. 2023)

View and export this data going back to 1997. Start your Free Trial

What is Nymox Pharmaceutical 3-Year EBITDA Growth Rate?

Nymox Pharmaceutical's EBITDA per Share for the three months ended in Sep. 2023 was $-0.01.

During the past 3 years, the average EBITDA Per Share Growth Rate was 27.30% per year. During the past 5 years, the average EBITDA Per Share Growth Rate was 18.20% per year. During the past 10 years, the average EBITDA Per Share Growth Rate was 6.70% per year. Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the average EBITDA per share growth rate.

During the past 13 years, the highest 3-Year average EBITDA Per Share Growth Rate of Nymox Pharmaceutical was 28.20% per year. The lowest was -27.40% per year. And the median was 1.80% per year.

Competitive Comparison of Nymox Pharmaceutical's 3-Year EBITDA Growth Rate

For the Biotechnology subindustry, Nymox Pharmaceutical's 3-Year EBITDA Growth Rate, along with its competitors' market caps and 3-Year EBITDA Growth Rate data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Nymox Pharmaceutical's 3-Year EBITDA Growth Rate Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Nymox Pharmaceutical's 3-Year EBITDA Growth Rate distribution charts can be found below:

* The bar in red indicates where Nymox Pharmaceutical's 3-Year EBITDA Growth Rate falls into.

Nymox Pharmaceutical 3-Year EBITDA Growth Rate Calculation

This is the 3-year average growth rate of EBITDA per Share. The growth rate is calculated using exponential compounding based on the latest four year annual data.

Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the average EBITDA per share growth rate.

Nymox Pharmaceutical (OTCPK:NYMXF) 3-Year EBITDA Growth Rate Explanation

EBITDA per Share is the amount of Earnings Before Interest, Taxes, Depreciation, and Amortization (EBITDA) per outstanding share of the company's stock.

Earnings Before Interest, Taxes, Depreciation, and Amortization (EBITDA) is what the company earns before it expenses interest, taxes, depreciation and amortization.

Nymox Pharmaceutical 3-Year EBITDA Growth Rate Related Terms

Thank you for viewing the detailed overview of Nymox Pharmaceutical's 3-Year EBITDA Growth Rate provided by GuruFocus.com. Please click on the following links to see related term pages.

Nymox Pharmaceutical (Nymox Pharmaceutical) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Nymox Pharmaceutical Corp (OTCPK:NYMXF) » Definitions » 3-Year EBITDA Growth Rate

Comparable Companies

Traded in Other Exchanges

N/A

Address

Bay & Deveaux Streets, Nassau, BHS

Website

https://www.nymox.com

Nymox Pharmaceutical Corp is a biopharmaceutical company focused on developing its drug candidate, NX-1207, for the treatment of BPH and the treatment of low-grade localized prostate cancer. It markets NicAlert and TobacAlert tests that use urine or saliva to detect use of tobacco products. It operates in a single segment, which is research and development of products for the aging population. The company's geographical segments include Canada, United States, and Europe.

Executives

James George Robinson	director	10 EAST LEE STREET, SUITE 2705, BALTIMORE MD 21202
Erik Danielsen	officer: Chief Financial Officer	9900 CAVENDISH BLVD, ST LAURENT A8 H4M 2V2
Paul Averback	director, 10 percent owner, officer: CEO	C/O NYMOX PHARMACEUTICAL CORPORATION, 9900 CAVENDISH BLVD., SUITE 306, ST. LAURENT A8 H4M 2V2
Randall J Lanham	director, officer: General Counsel